Ligand Pharmaceuticals (LGND) Liabilities and Shareholders Equity (2010 - 2026)

Ligand Pharmaceuticals' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $1.5 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 69.21% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $5.5 billion (up 50.42% YoY), while the FY2025 annual figure was $1.6 billion, up 65.71% from the prior year.
• Liabilities and Shareholders Equity came in at $1.5 billion for Q1 2026 at Ligand Pharmaceuticals, down from $1.6 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.6 billion in Q4 2025 to a low of $758.1 million in Q2 2023.
• A 5-year average of $1.0 billion and a median of $941.8 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity sank 41.22% in 2022 and soared 69.21% in 2026, its largest moves.
• Ligand Pharmaceuticals' Liabilities and Shareholders Equity stood at $762.7 million in 2022, then advanced by 3.22% to $787.2 million in 2023, then climbed by 19.63% to $941.8 million in 2024, then soared by 65.71% to $1.6 billion in 2025, then dropped by 1.83% to $1.5 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $1.5 billion, $1.6 billion, and $1.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison